DLA Piper welcomes Josh Kaufman as co-chair of Capital Markets & Public Company Advisory Practice

DLA Piper is pleased to welcome Joshua A. Kaufman as co-chair of its Capital Markets and Public Company Advisory Practice based out of the firm’s New York and Miami offices.

Kaufman is a commercially oriented corporate counselor who advises high growth businesses on financing pathways, strategic development and transformational transactions. He is well-versed in cross-border matters, having advised leading innovative companies in the United Kingdom, the Nordics, Continental Europe and Israel.

Kaufman represents US and foreign private issuers and underwriters, primarily in the life sciences and technology sectors, in a wide variety of public offerings and private placements. He has advised on more than 200 financing transactions with an aggregate value in excess of US$100 billion. He frequently represents clients before the Securities and Exchange Commission, and advises on corporate governance, general corporate and commercial matters. 

His notable experience includes representing underwriting syndicates in the first dual listings of Danish and Swedish companies in the US, a New York biotech in its US$40 million IPO and numerous follow-on offerings, a national restaurant chain in its US$140 million primary and US$75 million at-the-market offerings, a UK-listed biotech in its transition to Nasdaq and numerous follow-on offerings, as well as four IPOs out of Israel aggregating US$1.2 billion.

“Josh’s strong cross-border practice and vast knowledge of the increasingly complex transactional landscape, especially in rapidly growing sectors like life sciences and technology, will further invigorate the positive momentum of our capital market practice,” said Era Anagnosti, co-chair of DLA Piper’s Capital Markets and Public Company Advisory practice. “His experience and leadership will be strong assets for our team and our clients, and we’re eager to have him on board.”

“We are actively expanding our capital markets, M&A and venture capital capabilities in the life sciences and technology sectors, and we are confident that Josh will provide a significant addition to our strong capital markets team in these key sectors,” said Andy Gilbert, DLA Piper’s chair of the US Corporate practice.

DLA Piper’s global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.

DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.